Processa Pharmaceuticals, Inc. (PCSA): Price and Financial Metrics


Processa Pharmaceuticals, Inc. (PCSA): $2.52

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PCSA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PCSA Stock Price Chart Interactive Chart >

Price chart for PCSA

PCSA Price/Volume Stats

Current price $2.52 52-week high $8.99
Prev. close $2.52 52-week low $1.50
Day low $2.38 Volume 38,400
Day high $2.56 Avg. volume 33,622
50-day MA $2.77 Dividend yield N/A
200-day MA $4.86 Market Cap 39.91M

Processa Pharmaceuticals, Inc. (PCSA) Company Bio


Processa Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. Processa Pharmaceuticals serves patients in the United States.


PCSA Latest News Stream


Event/Time News Detail
Loading, please wait...

PCSA Latest Social Stream


Loading social stream, please wait...

View Full PCSA Social Stream

Latest PCSA News From Around the Web

Below are the latest news stories about Processa Pharmaceuticals Inc that investors may wish to consider to help them evaluate PCSA as an investment opportunity.

Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022

HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young. Dear Fellow Shareholder: As we start a new year, I want to thank you for your support and

Yahoo | January 26, 2022

Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | January 17, 2022

Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update

Clinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022 HANOVER, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announces financial results for the quarter ended September 30, 2021, and provides a corporate update. Dr. David

Yahoo | November 11, 2021

Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis

Next Generation Capecitabine inhibited DPD activity 24-48 hours after PCS6422 administration with < 10% of 5-FU metabolized to FBAL compared to 80% reported for FDA approved capecitabine.24-48 hours after PCS6422 administration, 5-FU potency based on systemic exposure per mg of capecitabine was at least 50 x greater than reported for FDA approved capecitabine.The improved metabolism profile and increased potency did not exist 7 days after PCS6422 administration.The timeline of DPD inhibition and

Yahoo | November 4, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST

HANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that the Company will report financial results for the quarter ended September 30, 2021 on Thursday November 11, 2021. The Company will host a conference call at 5:30 p.m. Eastern Time on Thursday November

Yahoo | October 26, 2021

Read More 'PCSA' Stories Here

PCSA Price Returns

1-mo -9.03%
3-mo -34.20%
6-mo -53.85%
1-year -59.02%
3-year N/A
5-year N/A
YTD -48.57%
2021 -25.70%
2020 N/A
2019 0.00%
2018 -18.18%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8224 seconds.